Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04

Axe Compute Inc.

Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.
Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.
Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.
Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.
FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).

Period: the quarter ended March 31, 2024
Revenue: $419,646
Net income: net loss of approximately $4.2 million
EPS: $(1.04)
Result: reported results

Exact text from the filing

share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived

View on SEC.gov

Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.